George M. Milne Jr. - 16 Mar 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol
AMLX
Transactions as of
16 Mar 2023
Net transactions value
-$1,116,072
Form type
4
Filing time
20 Mar 2023, 20:25:57 UTC
Previous filing
06 Mar 2023
Next filing
23 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Sale $1,053,901 -33,084 -3.7% $31.86 863,937 16 Mar 2023 Direct F1, F2
transaction AMLX Common Stock Sale $62,172 -1,916 -0.22% $32.45 862,021 16 Mar 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 16, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.30 to $32.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.30 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.